121.05
price up icon1.04%   1.25
after-market アフターアワーズ: 120.50 -0.55 -0.45%
loading
前日終値:
$119.80
開ける:
$119.98
24時間の取引高:
466.85K
Relative Volume:
0.56
時価総額:
$10.07B
収益:
$51.48M
当期純損益:
$-315.00M
株価収益率:
-33.90
EPS:
-3.5708
ネットキャッシュフロー:
$-244.00M
1週間 パフォーマンス:
-0.30%
1か月 パフォーマンス:
+9.48%
6か月 パフォーマンス:
+33.01%
1年 パフォーマンス:
+174.49%
1日の値動き範囲:
Value
$116.46
$121.56
1週間の範囲:
Value
$116.46
$127.36
52週間の値動き範囲:
Value
$39.84
$130.05

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1033)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
253
Name
Twitter
Name
次回の収益日
2026-08-10
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

Compare KYMR vs VRTX, REGN, ARGX, MRNA, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KYMR icon
KYMR
Kymera Therapeutics Inc
121.05 10.10B 51.48M -315.00M -244.00M -3.5708
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
547.59 136.93B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
828.50 85.11B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
1,011.11 64.95B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
138.89 53.23B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
211.58 45.38B 742.00K -1.37B -1.07B -7.0731

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-05-06 開始されました Canaccord Genuity Buy
2026-03-16 再開されました Jefferies Buy
2026-01-28 再開されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-03 再開されました Guggenheim Buy
2025-10-24 繰り返されました B. Riley Securities Buy
2025-10-21 開始されました Mizuho Outperform
2025-09-18 繰り返されました H.C. Wainwright Buy
2025-09-17 開始されました Barclays Overweight
2025-09-16 開始されました RBC Capital Mkts Outperform
2025-07-30 再開されました B. Riley Securities Buy
2025-07-03 再開されました Morgan Stanley Overweight
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
Aug 21, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 21, 2026
pulisher
Aug 20, 2026

Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo

Aug 20, 2026
pulisher
Aug 20, 2026

B of A, Truist raise Kymera Therapeutics price targets - scanx.trade

Aug 20, 2026
pulisher
Aug 20, 2026

Eagle Health Investments LP Buys Shares of 166,148 Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 20, 2026
pulisher
Aug 18, 2026

Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

Kymera Therapeutics, Inc. $KYMR Shares Sold by Bank of America Corp DE - MarketBeat

Aug 18, 2026
pulisher
Aug 17, 2026

Kymera Therapeutics (KYMR) Advances 3.42% to $121.41 as Protein Degradation Platform Gains Investor AttentionAnalyst Upgrade Stocks - vinanet.vn

Aug 17, 2026
pulisher
Aug 17, 2026

Kymera Therapeutics Inc (KYMR) (Q2 2026) Earnings Call Highlight - GuruFocus

Aug 17, 2026
pulisher
Aug 17, 2026

Kymera Therapeutics Stock Rockets 17% With 9-Day Winning Streak - Trefis

Aug 17, 2026
pulisher
Aug 17, 2026

A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17% - Trefis

Aug 17, 2026
pulisher
Aug 16, 2026

State of Wyoming Purchases New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 16, 2026
pulisher
Aug 14, 2026

Kymera Therapeutics (KYMR) Edges Higher by 1.4% as Shares Test Key Resistance at $121.87IV Spike - Vinanet

Aug 14, 2026
pulisher
Aug 14, 2026

T. Rowe Price Associates (KYMR) reports 8.6% stake in Kymera Therapeutics - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14% - Trefis

Aug 14, 2026
pulisher
Aug 14, 2026

A 8-Day Winning Streak Has Kymera Therapeutics Stock Up 14% - Trefis

Aug 14, 2026
pulisher
Aug 13, 2026

Atlas Venture funds (KYMR) report 3.4% beneficial stake in Kymera Therapeutics - Stock Titan

Aug 13, 2026
pulisher
Aug 13, 2026

Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $132 - Moomoo

Aug 13, 2026
pulisher
Aug 12, 2026

Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript - The Globe and Mail

Aug 12, 2026
pulisher
Aug 11, 2026

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail

Aug 11, 2026
pulisher
Aug 11, 2026

Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat

Aug 11, 2026
pulisher
Aug 11, 2026

(KYMR) Volatility Zones as Tactical Triggers - Stock Traders Daily

Aug 11, 2026
pulisher
Aug 10, 2026

HC Wainwright Issues Negative Outlook for KYMR Earnings - MarketBeat

Aug 10, 2026
pulisher
Aug 08, 2026

BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $123 - Moomoo

Aug 08, 2026
pulisher
Aug 08, 2026

California State Teachers Retirement System Increases Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Aug 08, 2026
pulisher
Aug 07, 2026

J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $121 - Moomoo

Aug 07, 2026
pulisher
Aug 07, 2026

Why Kymera Therapeutics (NASDAQ:KYMR) Is Drawing Fresh Attention This Week? - Kalkine Media

Aug 07, 2026
pulisher
Aug 07, 2026

A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $116 to $139 - Moomoo

Aug 07, 2026
pulisher
Aug 07, 2026

Q3 EPS Forecast for Kymera Therapeutics Cut by Analyst - MarketBeat

Aug 07, 2026
pulisher
Aug 07, 2026

RBC Capital Downgrades Kymera Therapeutics(KYMR.US) to Hold Rating, Raises Target Price to $112 - moomoo.com

Aug 07, 2026
pulisher
Aug 06, 2026

KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments - finance.yahoo.com

Aug 06, 2026
pulisher
Aug 06, 2026

KYMR Maintains Overweight by Barclays -- Price Target Raised to $139 - GuruFocus

Aug 06, 2026
pulisher
Aug 06, 2026

KYMERA THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $135 FROM $120 - Bitget

Aug 06, 2026
pulisher
Aug 06, 2026

Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning - simplywall.st

Aug 06, 2026
pulisher
Aug 06, 2026

Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR) - finance.yahoo.com

Aug 06, 2026
pulisher
Aug 06, 2026

KYMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Aug 06, 2026
pulisher
Aug 05, 2026

KYMR Looks 328.3% Overvalued on GF Value™ - GuruFocus

Aug 05, 2026
pulisher
Aug 05, 2026

Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 05, 2026
pulisher
Aug 05, 2026

Kymera Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-08-05 - Seeking Alpha

Aug 05, 2026
pulisher
Aug 05, 2026

Kymera Therapeutics, Inc. Stock 12‑Month Price Target Raised to $128.91, Implies 23% Upside - TradingView

Aug 05, 2026
pulisher
Aug 05, 2026

Kymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat

Aug 05, 2026
pulisher
Aug 05, 2026

Kymera Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 05, 2026
pulisher
Aug 05, 2026

Kymera Therapeutics Q2 Earnings Call Highlights - MarketBeat

Aug 05, 2026
pulisher
Aug 05, 2026

Is Kymera Therapeutics Inc (KYMR) Overvalued After Q2 Earnings B - GuruFocus

Aug 05, 2026
pulisher
Aug 05, 2026

Earnings call transcript: Kymera beats Q2 2026 estimates on revenue surge - Investing.com

Aug 05, 2026
pulisher
Aug 05, 2026

Kymera Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 05, 2026
pulisher
Aug 05, 2026

Kymera Therapeutics Q2 Net Loss Narrows, Collaboration Revenue Rises - marketscreener.com

Aug 05, 2026
pulisher
Aug 05, 2026

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Aug 05, 2026
pulisher
Aug 05, 2026

Earnings Flash (KYMR) Kymera Therapeutics Posts Q2 Loss $0.62 a Share, vs. FactSet Est of $0.71 Loss - marketscreener.com

Aug 05, 2026
pulisher
Aug 05, 2026

Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q2 Collaboration Revenue $65.0M, vs. FactSet Est of $32.8M - marketscreener.com

Aug 05, 2026
pulisher
Aug 05, 2026

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - The Manila Times

Aug 05, 2026

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$123.98
price up icon 0.00%
$61.33
price up icon 0.03%
$112.82
price down icon 3.22%
$236.01
price down icon 0.09%
ONC ONC
$371.98
price down icon 0.66%
$211.58
price up icon 1.01%
大文字化:     |  ボリューム (24 時間):